• Tue news: Novo looks to speed up India Wegovy launch. 4 revelations from MN’s 340B transparency report. 4 oral GLP-1R’s in dev. Roche autoimmune partnership. Gilead-Tubulis alliance. See more on our front page

Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 20, 2024 at 08:52: PM
via To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates. Novartis will then potentially move candidates forward through the clinic, according to a Nov. 20 release.

article source
 






Top Bottom
Back
Quote